{
 "cells": [
  {
   "cell_type": "raw",
   "metadata": {},
   "source": [
    "---\n",
    "title: \"Reference finder\"\n",
    "subtitle: \"Find claims and their variations in an input pdf file\"\n",
    "author: \"Faraz Ahmadi\"\n",
    "date: \"2024-03-16\"\n",
    "format:\n",
    "  pdf:\n",
    "    toc: false\n",
    "    number-sections: true\n",
    "    colorlinks: true\n",
    "    code-block-theme: github\n",
    "---"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Extracting claims from the email data\n",
    "\n",
    "This would create a list of claims extracted from the TREMFYA marketing email. Every claim's corresponding reference is also provided."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 168,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>reference</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>When your patient presents with moderate-to-se...</td>\n",
       "      <td>[PM p. 4A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>TREMFYA®/TREMFYA ONE-PRESS® (guselkumab inject...</td>\n",
       "      <td>[PM p. 4A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>HEAD-TO-HEAD RESULTS: TREMFYA® 48-WEEK EFFICAC...</td>\n",
       "      <td>[ECLIPSE p 5A, 5B, 6A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>In a phase 3, multicentre, randomized, double-...</td>\n",
       "      <td>[COPY]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>&lt;“PASI 90” icon&gt; TREMFYA® demonstrated a super...</td>\n",
       "      <td>[ECLIPSE p 5A, 5B, 6A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>TREMFYA®: THE FIRST IL-23 INHIBITOR WITH INDIC...</td>\n",
       "      <td>[DOF Letter, March 2, 2021, p1A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Indication not previously mentioned and clinic...</td>\n",
       "      <td>[PM p. 4B]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Do not initiate treatment in patients with any...</td>\n",
       "      <td>[PM p. 7A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Discontinue treatment if patient develops a se...</td>\n",
       "      <td>[PM p. 7B]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Evaluate patients for tuberculosis infection p...</td>\n",
       "      <td>[PM p. 7C]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text  \\\n",
       "0  When your patient presents with moderate-to-se...   \n",
       "1  TREMFYA®/TREMFYA ONE-PRESS® (guselkumab inject...   \n",
       "2  HEAD-TO-HEAD RESULTS: TREMFYA® 48-WEEK EFFICAC...   \n",
       "3  In a phase 3, multicentre, randomized, double-...   \n",
       "4  <“PASI 90” icon> TREMFYA® demonstrated a super...   \n",
       "5  TREMFYA®: THE FIRST IL-23 INHIBITOR WITH INDIC...   \n",
       "6  Indication not previously mentioned and clinic...   \n",
       "7  Do not initiate treatment in patients with any...   \n",
       "8  Discontinue treatment if patient develops a se...   \n",
       "9  Evaluate patients for tuberculosis infection p...   \n",
       "\n",
       "                          reference  \n",
       "0                        [PM p. 4A]  \n",
       "1                        [PM p. 4A]  \n",
       "2            [ECLIPSE p 5A, 5B, 6A]  \n",
       "3                            [COPY]  \n",
       "4            [ECLIPSE p 5A, 5B, 6A]  \n",
       "5  [DOF Letter, March 2, 2021, p1A]  \n",
       "6                        [PM p. 4B]  \n",
       "7                        [PM p. 7A]  \n",
       "8                        [PM p. 7B]  \n",
       "9                        [PM p. 7C]  "
      ]
     },
     "execution_count": 168,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "from PyPDF2 import PdfReader\n",
    "import re\n",
    "from pdfplumber import pdf\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from sentence_transformers import SentenceTransformer, util\n",
    "import torch\n",
    "import sys,time,random\n",
    "import spacy\n",
    "from spacypdfreader.spacypdfreader import pdf_reader\n",
    "\n",
    "claims = pd.read_excel(r'data\\Tremfya_email_claims.xlsx')\n",
    "claims.head()\n",
    "\n",
    "# using regex extract all text not between []\n",
    "ext_claims = []\n",
    "ext_refs = []\n",
    "for i in range(len(claims)):\n",
    "    my_str = claims.iloc[i].squeeze()\n",
    "    ext_claims.append(re.sub(r'\\[.*?\\]', '', my_str))\n",
    "    ext_refs.append(re.findall(r'\\[.*?\\]', my_str)[-1])\n",
    "\n",
    "claims['text'] = ext_claims\n",
    "claims['text'] = claims['text'].str.replace('\\n', '').str.strip()\n",
    "claims['reference'] = ext_refs\n",
    "claims[['text', 'reference']].head(10)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 169,
   "metadata": {},
   "outputs": [],
   "source": [
    "def progressBar(count_value, total, suffix=''):\n",
    "    bar_length = 100\n",
    "    filled_up_Length = int(round(bar_length* count_value / float(total)))\n",
    "    percentage = round(100.0 * count_value/float(total),1)\n",
    "    bar = '=' * filled_up_Length + '-' * (bar_length - filled_up_Length)\n",
    "    sys.stdout.write('[%s] %s%s ...%s\\r' %(bar, percentage, '%', suffix))\n",
    "    sys.stdout.flush()\n",
    "\n",
    "# Loading the llm model here\n",
    "# llm = GPT4All(\"orca-mini-3b.ggmlv3.q4_0.bin\")\n",
    "\n",
    "def get_query():\n",
    "    query = input(\"Enter your question\\n\")\n",
    "    progressBar(1, 7)\n",
    "    return query\n",
    "\n",
    "\n",
    "def load_split_pdf(pdf_path):\n",
    "    pdf_loader = PdfReader(open(pdf_path, \"rb\"))\n",
    "    pdf_text = \"\"\n",
    "    for page_num in range(len(pdf_loader.pages)):\n",
    "        pdf_page = pdf_loader.pages[page_num]\n",
    "        pdf_text += pdf_page.extract_text()\n",
    "    progressBar(2, 7)\n",
    "    return pdf_text\n",
    "\n",
    "def load_pdf_spacy(pdf_path):\n",
    "    nlp = spacy.load('en_core_web_sm')\n",
    "    doc = pdf_reader(pdf_path, nlp)\n",
    "    return doc\n",
    "\n",
    "\n",
    "\n",
    "def split_text_using_RCTS(pdf_text):\n",
    "    text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=2096,\n",
    "    chunk_overlap=1024, #not sure about the effect of these\n",
    "    keep_separator=True #not sure about the effect of these\n",
    "    )\n",
    "    split_texts = text_splitter.split_text(pdf_text)\n",
    "    paragraphs = []\n",
    "    for text in split_texts:\n",
    "        # text.replace(r'(?<!\\n)(\\n)(?=\\s*[A-Z][a-z])', '\\n')\n",
    "        splitted_text = text.split('\\n\\n')\n",
    "        splitted_text = [text.replace('\\n', '').strip() for text in splitted_text]\n",
    "        paragraphs.extend(splitted_text) \n",
    "    progressBar(3, 7)\n",
    "    return paragraphs, split_texts\n",
    "\n",
    "\n",
    "\n",
    "def Initialize_sentence_transformer():\n",
    "    model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "    embedder = SentenceTransformer(model_name)\n",
    "    progressBar(3, 7)\n",
    "    return embedder\n",
    "\n",
    "\n",
    "def encode_each_paragraph(paragraphs, embedder):\n",
    "    corpus_embeddings = embedder.encode(paragraphs, convert_to_tensor=True)\n",
    "    progressBar(5, 7)\n",
    "    return corpus_embeddings\n",
    "\n",
    "def choose_most_relevant_sentence(embedder, corpus_embeddings, query, k:int=5):\n",
    "    query_embedding = embedder.encode(query, convert_to_tensor=True)\n",
    "    top_k = min(k, len(corpus_embeddings))\n",
    "\n",
    "    # We use cosine-similarity and torch.topk to find the highest 5 scores\n",
    "    cos_scores = util.cos_sim(query_embedding, corpus_embeddings)[0]\n",
    "    top_results = torch.topk(cos_scores, k=top_k)\n",
    "    progressBar(6, 7)\n",
    "    return top_results\n",
    "\n",
    "\n",
    "\n",
    "def find_paragraph_in_pdf(paragraph, pdf_doc):\n",
    "    for page_number in range(1, pdf_doc._.page_range[1] + 1):\n",
    "        page = pdf_doc._.page(page_number)\n",
    "        # the replace would cause the index to be off a bit but it's the only way to deal with the new lines in middle of the paragraph\n",
    "        res = page.text.replace('\\n','').find(paragraph)\n",
    "        if res != -1:\n",
    "            return page_number, res, res + len(paragraph)\n",
    "    return None\n",
    "\n",
    "def print_results(query, top_results, paragraphs, pdf_doc):\n",
    "    progressBar(7, 7)\n",
    "    print(\"Query (claim):\", query)\n",
    "    print(\"\\nTop 10 most similar sentences in pdf:\")\n",
    "    for score, idx in zip(top_results[0], top_results[1]):\n",
    "        print(f\"(Score: {score:.4f})\", paragraphs[idx],)\n",
    "        res = find_paragraph_in_pdf(paragraphs[idx], pdf_doc)\n",
    "        if res:\n",
    "            print(f\"Found in page {res[0]} (start: {res[1]}, end: {res[2]})\")\n",
    "        else:\n",
    "            print(\"Not found in pdf\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 145,
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Using spacy, made the paragraphs much accurate\n",
    "# pdf_path = 'data/MASTER_TremfyaPM_08Nov2022_annotated.pdf'\n",
    "# # doc = load_pdf_spacy(pdf_path)\n",
    "# text = doc._.page(4).text\n",
    "# paragraphs, split_texts = split_text_using_RCTS(text)\n",
    "# paragraphs"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Read pdf and find similar sentences to claim\n",
    "\n",
    "By specifying the row number in that initial claims data set and giving the input location of the pdf, the code will extract the reference for that claim using semantic similarity and would find the most similar sentence in the pdf with it's page number and location in the page.\n",
    "\n",
    "The code would also provide the similarity score between the claim and the sentence and print the top 10 results based on that.\n",
    "\n",
    "A few claims were tested and the results were found to be accurate.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 164,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: TREMFYA®/TREMFYA ONE-PRESS® (guselkumab injection) is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.2\n",
      "\n",
      "Top 10 most similar sentences in corpus:\n",
      "(Score: 0.9558) TREMFYA®/TREMFYA One-Press® (guselkumab injection) should be prescribed by physicians who have sufficient knowledge of plaque psoriasis or psoriatic arthritis and who have fully familiarized themselves with the efficacy/safety profile of the drug.\n",
      "Found in page 1 (start: 275, end: 522)\n",
      "(Score: 0.8822) TREMFYA®/TREMFYA One-Press® (guselkumab injection) is indicated for:\n",
      "Found in page 4 (start: 67, end: 135)\n",
      "(Score: 0.8822) TREMFYA®/TREMFYA One-Press® (guselkumab injection) is indicated for:\n",
      "Found in page 4 (start: 67, end: 135)\n",
      "(Score: 0.8822) TREMFYA®/TREMFYA One-Press® (guselkumab injection) is indicated for:\n",
      "Found in page 4 (start: 67, end: 135)\n",
      "(Score: 0.8822) TREMFYA®/TREMFYA One-Press® (guselkumab injection) is indicated for:\n",
      "Found in page 4 (start: 67, end: 135)\n",
      "(Score: 0.8742) TREMFYA®/TREMFYA One-Press® contains the active substance guselkumab. Guselkumab is a monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind specifically to certain proteins in the body. This medicine works by neutralizing the activity of a protein called IL-23, which is present at increased levels in diseases such as plaque psoriasis.\n",
      "Found in page 27 (start: 1664, end: 2026)\n",
      "(Score: 0.8705) TREMFYA®/TREMFYA One-Press® (guselkumab injection) is a fully human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody (mAb) that binds selectively to the extracellular human interleukin 23 (IL-23) protein with high specificity and affinity. Guselkumab is produced in a mammalian cell line using recombinant DNA technology.\n",
      "Found in page 6 (start: 1667, end: 1992)\n",
      "(Score: 0.8705) TREMFYA®/TREMFYA One-Press® (guselkumab injection) is a fully human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody (mAb) that binds selectively to the extracellular human interleukin 23 (IL-23) protein with high specificity and affinity. Guselkumab is produced in a mammalian cell line using recombinant DNA technology.\n",
      "Found in page 6 (start: 1667, end: 1992)\n",
      "(Score: 0.8597) TREMFYA®/TREMFYA One-Press® is a prescription medicine used to treat adults with moderate to severe “plaque psoriasis”, an inflammatory condition affecting the skin and nails. Plaque psoriasis can cause raised, thick, red and scaly patches (“psoriatic lesions”) that can appear anywhere on your body. TREMFYA®/TREMFYA One-Press® reduces the inflammation and other symptoms of the disease.\n",
      "Found in page 27 (start: 568, end: 956)\n",
      "(Score: 0.8558) TREMFYA®/TREMFYA One-Press® is contraindicated in patients with known serious hypersensitivity to guselkumab or any of the components. For a complete listing of components, see the 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING section.\n",
      "Found in page 4 (start: 1036, end: 1278)\n"
     ]
    }
   ],
   "source": [
    "pdf_path = 'data/MASTER_TremfyaPM_08Nov2022_annotated.pdf'\n",
    "query = claims['text'][1]\n",
    "pdf_doc = load_pdf_spacy(pdf_path)\n",
    "paragraphs, _ = split_text_using_RCTS(pdf_doc.text)\n",
    "embedder = Initialize_sentence_transformer()\n",
    "corpus_embedding = encode_each_paragraph(paragraphs=paragraphs, embedder=embedder)\n",
    "top_results = choose_most_relevant_sentence(embedder, corpus_embedding, query, k = 10)\n",
    "print_results(query, top_results, paragraphs, pdf_doc)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 166,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query reference: [COPY]\n",
      "[====================================================================================================] 100.0% ...\r"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: In a phase 3, multicentre, randomized, double-blind, comparator-controlled study (ECLIPSE) with fixed-sequence non-inferiority/superiority testing:\n",
      "\n",
      "Top 10 most similar sentences in corpus:\n",
      "(Score: 0.5537) VOYAGE 1 A phase 3, multicenter, randomized, double-blind, placebo and active comparator controlled study\n",
      "Found in page 17 (start: 1131, end: 1236)\n",
      "(Score: 0.5537) VOYAGE 1 A phase 3, multicenter, randomized, double-blind, placebo and active comparator controlled study\n",
      "Found in page 17 (start: 1131, end: 1236)\n",
      "(Score: 0.5448) A phase 3, multicenter, randomized, double-blind, placebo-controlled study\n",
      "Found in page 21 (start: 2276, end: 2350)\n",
      "(Score: 0.5448) A phase 3, multicenter, randomized, double-blind, placebo-controlled study\n",
      "Found in page 21 (start: 2276, end: 2350)\n",
      "(Score: 0.5448) A phase 3, multicenter, randomized, double-blind, placebo-controlled study\n",
      "Found in page 21 (start: 2276, end: 2350)\n",
      "(Score: 0.5427) VOYAGE 2 A phase 3, multicenter, randomized, double-blind, placebo and active comparator controlled study\n",
      "Found in page 18 (start: 0, end: 105)\n",
      "(Score: 0.5427) VOYAGE 2 A phase 3, multicenter, randomized, double-blind, placebo and active comparator controlled study\n",
      "Found in page 18 (start: 0, end: 105)\n",
      "(Score: 0.5427) VOYAGE 2 A phase 3, multicenter, randomized, double-blind, placebo and active comparator controlled study\n",
      "Found in page 18 (start: 0, end: 105)\n",
      "(Score: 0.3769) IGA response of 0/1PASI 90 responsea Non-responder imputation.b Treatment difference versus placebo adjusted by investigator site with Mantel-Haenszel weights.c p-value < 0.001; p-value is based on the Cochran-Mantel-Haenszel chi-square test stratified by investigator site.\n",
      "Found in page 19 (start: 910, end: 1184)\n",
      "(Score: 0.3522) A greater proportion of subjects in the guselkumab group achieved an IGA score of 0 or 1 or a PASI 90 response at Week 16 (81% and 76%, respectively) than in the placebo group (0% for both endpoints). The proportion of subjects who achieved an IGA score of 0 at Week 16 was higher in the guselkumab group compared to the placebo group (56.5% vs. 0%). The proportion of subjects who achieved a PASI 100 response at Week 16 was higher in the guselkumab group compared to the placebo group (50.0% vs. 0%).\n",
      "Found in page 21 (start: 1597, end: 2099)\n"
     ]
    }
   ],
   "source": [
    "# now we can use the same code to find the relevant paragraph for the other queries\n",
    "i = 3\n",
    "query = claims['text'][i]\n",
    "print('Query reference:', claims['reference'][i])\n",
    "top_results = choose_most_relevant_sentence(embedder, corpus_embedding, query, k = 10)\n",
    "print_results(query, top_results, paragraphs, pdf_doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 167,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query reference: [PM p. 4B]\n",
      "Query: Indication not previously mentioned and clinical use:TREMFYA®/TREMFYA ONE-PRESS® is also indicated for the treatment of adult patients with active psoriatic arthritis. TREMFYA®/TREMFYA ONE-PRESS® can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).\n",
      "\n",
      "Top 10 most similar sentences in corpus:\n",
      "(Score: 0.9521) the treatment of adult patients with active psoriatic arthritis. TREMFYA®/TREMFYA One-Press® can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).\n",
      "Found in page 4 (start: 355, end: 571)\n",
      "(Score: 0.9521) the treatment of adult patients with active psoriatic arthritis. TREMFYA®/TREMFYA One-Press® can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).\n",
      "Found in page 4 (start: 355, end: 571)\n",
      "(Score: 0.9489) TREMFYA®/TREMFYA One-Press® is used to treat adults with active psoriatic arthritis. Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. Psoriatic arthritis can cause pain, swelling and stiffness in the joints, in addition to a disruption in daily activities and fatigue. If you have active psoriatic arthritis, you will be given TREMFYA®/TREMFYA One-Press® alone or in combination with a conventional Disease Modifying Anti-Rheumatic Drug (cDMARD) such as methotrexate. TREMFYA®/TREMFYA One-Press® reduces signs and symptoms of your arthritis and may improve symptoms in patients that have psoriasis.\n",
      "Found in page 27 (start: 977, end: 1622)\n",
      "(Score: 0.9489) TREMFYA®/TREMFYA One-Press® is used to treat adults with active psoriatic arthritis. Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. Psoriatic arthritis can cause pain, swelling and stiffness in the joints, in addition to a disruption in daily activities and fatigue. If you have active psoriatic arthritis, you will be given TREMFYA®/TREMFYA One-Press® alone or in combination with a conventional Disease Modifying Anti-Rheumatic Drug (cDMARD) such as methotrexate. TREMFYA®/TREMFYA One-Press® reduces signs and symptoms of your arthritis and may improve symptoms in patients that have psoriasis.\n",
      "Found in page 27 (start: 977, end: 1622)\n",
      "(Score: 0.9188) TREMFYA®/TREMFYA One-Press® is a prescription medicine used to treat adults with moderate to severe “plaque psoriasis”, an inflammatory condition affecting the skin and nails. Plaque psoriasis can cause raised, thick, red and scaly patches (“psoriatic lesions”) that can appear anywhere on your body. TREMFYA®/TREMFYA One-Press® reduces the inflammation and other symptoms of the disease.\n",
      "Found in page 27 (start: 568, end: 956)\n",
      "(Score: 0.8948) TREMFYA®/TREMFYA One-Press® can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).\n",
      "Found in page 4 (start: 420, end: 571)\n",
      "(Score: 0.8948) TREMFYA®/TREMFYA One-Press® can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).\n",
      "Found in page 4 (start: 420, end: 571)\n",
      "(Score: 0.8657) TREMFYA®/TREMFYA One-Press® is a selective immunomodulatory agent which has the potential to increase the risk of infection. Infections have been observed in clinical trials in plaque psoriasis (23% vs 21% for placebo; ≤ 0.2% serious infections in both groups) and psoriatic arthritis (21% in both TREMFYA® and placebo groups; ≤ 0.8% serious infections in both groups). The most common type of infection reported was respiratory tract infection. (See 8 ADVERSE REACTIONS, Infections)\n",
      "Found in page 7 (start: 455, end: 938)\n",
      "(Score: 0.8657) TREMFYA®/TREMFYA One-Press® is a selective immunomodulatory agent which has the potential to increase the risk of infection. Infections have been observed in clinical trials in plaque psoriasis (23% vs 21% for placebo; ≤ 0.2% serious infections in both groups) and psoriatic arthritis (21% in both TREMFYA® and placebo groups; ≤ 0.8% serious infections in both groups). The most common type of infection reported was respiratory tract infection. (See 8 ADVERSE REACTIONS, Infections)\n",
      "Found in page 7 (start: 455, end: 938)\n",
      "(Score: 0.8459) TREMFYA®/TREMFYA One-Press® (guselkumab injection) should be prescribed by physicians who have sufficient knowledge of plaque psoriasis or psoriatic arthritis and who have fully familiarized themselves with the efficacy/safety profile of the drug.\n",
      "Found in page 1 (start: 275, end: 522)\n"
     ]
    }
   ],
   "source": [
    "i = 6\n",
    "query = claims['text'][i]\n",
    "print('Query reference:', claims['reference'][i])\n",
    "top_results = choose_most_relevant_sentence(embedder, corpus_embedding, query, k = 10)\n",
    "print_results(query, top_results, paragraphs, pdf_doc)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
